左西孟旦治疗难治性心力衰竭的有效性和安全性探讨

目的对难治性心力衰竭患者在常规药物治疗的基础上加用左西孟旦,探讨左西孟旦的有效性和安全性。方法将难治性心力衰竭患者108例随机分为观察组52例和对照组56例,对照组患者予以常规药物治疗（如利尿剂、地高辛等）,观察组患者予以常规治疗的同时加用左西孟旦静脉注射,两组均予以抗感染、限盐、限水、纠正诱发因素等基础治疗。观察两组患者的临床症状改善情况、左室射血分数以及不良反应的发生率。结果观察组患者的有效率（40.4%;25.0%）及总有效率（86.6%;60.7%）均显著高于对照组（P〈0.05）,无效率（13.4%;39.3%）显著低于对照组（P〈0.05）;观察组与对照组治疗后与治疗前相比,左室射血分数均有提高,但观察组提高的幅度明显高于对照组（P〈0.05）。结论左西孟旦可有效提高难治性心力衰竭患者的射血分数,具有较好的有效性和安全性。

The Observation of the Efficacy and Safety of Levosimendan in the Treatment of Refractory Heart Failure

Objective To observe the efficacy and safety of levosimendan on the basis of routine drug treatment for patients with refractory heart failure. Methods 108 cases of refractory heart failure patients were randomly divided into the observation group（n=52） and the control group（n=56）. Patients in the control group were given routine drug treatment, such as diuretic, digoxin and so on, the observation group patients were given intravenous injection of levosimendan on the basis of the conventional treatment. And both groups were also given the basic treatment such as anti-infection, limitation of salt and water, correcting the inducing factors and so forth. The improvement of clinical symptoms, left ventricular ejection fraction and the incidence of adverse reactions of two groups were observed. Results The effective rate（40.4%; 25.0%） and the total effective rate（86.6%, 60.7%） of observation group were significantly higher than those of control group（P〈0.05）; ineffective rate（13.4%; 39.3%） of observation group was significantly lower than that of control group（P〈0.05）. The left ventricular ejection fraction of both groups increased after treatment compared with that before treatment, but the increase rate of the observation group was significantly higher than that of the control group（P〈0.05）. Conclusion Levosimendan can effectively improve the ejection fraction in patients with refractory heart failure, and has better efficacy and safety.